Patients with chronic myeloid leukaemia (CML) who use the tyrosine kinase inhibitor (TKI) imatinib may be three to four times more likely to develop non-Hodgkin's lymphoma (NHL) than the general ...

Comparative clinical and molecular outcomes of first, second, and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia: A comprehensive Bayesian network meta-analysis. Hazard ratios ...

In Canada, Scemblix ® was previously approved for the treatment of adult patients with Ph+ CML-CP previously treated with two or more TKIs. Newly diagnosed patients will now have access to a treatment ...

Focusing on the initiation of treatment for newly diagnosed patients with CML, Jorge E. Cortes, MD, details important factors to consider when starting treatment and Claire Saxton discusses strategies ...

Nilotinib (Tasigna®) is a highly potent and selective inhibitor of breakpoint cluster region (BCR)–V-abl Abelson murine leukemia viral oncogene homolog 1 (ABL1), which was rationally designed based on ...

The survival prognosis for patients with chronic phase CML has greatly improved since the introduction of TKIs, with some studies showing life expectancy close to the general population. Nonetheless, ...

Leukemia and lymphoma are cancers that affect the blood or bone marrow. Fifteen percent of people with leukemia have chronic myeloid leukemia (CML), which has seen a 55% jump in new cases over the ...

Association of polypharmacy with acute care utilization in older adults receiving androgen receptor signaling inhibitors for metastatic prostate cancer. Understanding communication and healthcare ...

Experts on chronic myeloid leukemia discuss how caregivers can collaborate with the health care team and support newly diagnosed patients. In your work with caregivers, how have you seen them ...

MONTREAL, Dec. 10, 2025 /CNW/ - Novartis Canada is pleased to announce that Scemblix ® (asciminib) is one of the first therapies to be prioritized for public reimbursement under Ontario's new Funding ...